Status:
COMPLETED
COVID-19 Pandemic and Migraine Disorder, Tension Headache and Epilepsy
Lead Sponsor:
Aswan University
Conditions:
COVID-19
Eligibility:
All Genders
1-20 years
Brief Summary
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already rapidly spread around the world as a pandemic after its first report in Wuhan, Ch...
Detailed Description
Aim of the study: This study aims to: 1. Explore the possible changes in migraine\& tension headache frequency, severity during quarantine period. 2. Have a better understanding of the influence of ...
Eligibility Criteria
Inclusion
- Patient with migraine (with and without Aura) diagnosed according to the international classification of headache disorders 3rd edition ( ICHD-3)
- Patient with Chronic tension-type headache diagnosed according to ( ICHD-3)
- Patient with epilepsy diagnosed according to The International League Against Epilepsy (ILAE).
- Patients, whether they are infected or not infected with COVID-19.
Exclusion
- Age below 20years.
- Acute infarction or hemorrhage.
- Inability to respond to questionnaires.
- Severe medical illness.
- Drug or alcohol abuse.
- Patient with history of cerebrovascular stroke or TIA ,DM ,addiction, drugs as calcium blockers or beta blockers.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05205590
Start Date
June 1 2021
End Date
June 30 2022
Last Update
February 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University
Aswān, Egypt